Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The simulation hypothesis — the idea that our universe might be an artificial construct running on some advanced alien ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation ...

Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...

The MM+M editorial team was heartened by the progress made treating Alzheimer’s disease, the case of KJ Muldoon and ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

This study presents a valuable advance in reconstructing naturalistic speech from intracranial ECoG data using a dual-pathway model. The evidence supporting the claims of the authors is solid, ...

Standard Sections: Use clear headings like ‘Work Experience,’ ‘Education,’ and ‘Skills.’ List your most recent job first ...